Danielle Brill
Stock Analyst at Raymond James
(1.23)
# 3,519
Out of 4,876 analysts
75
Total ratings
32.81%
Success rate
-10.23%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $13.86 | +275.18% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $19.80 | +228.28% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $14.10 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $55.17 | +43.19% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $8.39 | +114.54% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $125.42 | +23.58% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $16.10 | +123.60% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $31.98 | +25.08% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $17.11 | +776.68% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $126.08 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $9.15 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $441.30 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $560.14 | +8.01% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.12 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $32.40 | +54.32% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $33.47 | +52.38% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $54.50 | -21.10% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.33 | +1,410.12% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $49.84 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.22 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $13.86
Upside: +275.18%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $19.80
Upside: +228.28%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.10
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $55.17
Upside: +43.19%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.39
Upside: +114.54%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $125.42
Upside: +23.58%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $16.10
Upside: +123.60%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $31.98
Upside: +25.08%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $17.11
Upside: +776.68%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $126.08
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $9.15
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $441.30
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $560.14
Upside: +8.01%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.12
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $32.40
Upside: +54.32%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $33.47
Upside: +52.38%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $54.50
Upside: -21.10%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.33
Upside: +1,410.12%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $49.84
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.22
Upside: -